Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 6—June 2005

Dispatch

Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–20031

Surbhi Malhotra-Kumar*Comments to Author , Christine Lammens*, Sabine Chapelle*, Monique Wijdooghe*, Jasper Piessens*, Koen Van Herck*, and Herman Goossens*
Author affiliations: *University of Antwerp, Antwerp, Belgium

Main Article

Table A2

Temporal changes in pulsed-field gel electrophoresis (PFGE) and emm type distribution among 3 macrolide-resistant Streptococcus pyogenes phenotypes

Macrolide-resistant phenotype Emm type PFGE cluster* Frequency (n=506) No. (%) of macrolide-resistant S. pyogenes
1999 (n=81) 2000 (n=41) 2001 (n=73) 2002 (n=215) 2003 (n=96)
cMLS emm22 1 70 45 (56) 7 (17) 9 (12) 7 (3) 2 (2)
1057 1 1 (0.4)
emm4 10 9 9 (12)
11 8 3 (4) 2 (3) 2 (1) 1 (1)
1002 1 1 (1)
1009 2 2 (5)
emm76 32 1 1 (1)
emm2 new2 1 1 (2)
emm28 4 45 4 (5) 15 (7) 26 (27)
emm11 23 28 1 (1) 6 (3) 21 (22)
emm75 15 1 1 (1)
emm6 5 1 1 (1)
emm12 6 1 1 (1)
57 11 8 (4) 3 (3)
emm77 10 6 6 (3)
NT† 2 3 3 (1)
49 12 12 (6)
64 4 4 (2)
65 1 1 (0.4)
69 2 2 (1)
70 1 1 (0.4)
M emm1 1001 128 7 (9) 12 (29) 23 (32) 80 (37) 6 (6)
1022 2 2 (2)
3 1 1 (1)
emm12 6 1 1 (0.4)
1011 10 4 (5) 2 (5) 3 (4) 1 (0.4)
1025 10 3 (4) 2 (1) 5 (5)
1026 2 2 (2)
1027 1 1 (1)
1030 2 1 (2) 1 (0.4)
1035 9 1 (1) 4 (2) 4 (4)
1044 1 1 (0.4)
1047 2 2 (1)
emm2 18 1 1 (1)
1038 1 1 (1)
new 3 1 1(1)
1042 1 1 (0.4)
1034 1 1 (1)
1049 1 1 (0.4)
emm4 1002 28 2 (2.5) 2 (5) 7 (10) 7 (3) 10 (10)
1007 2 2 (5)
1008 1 1 (1)
1009 1 1 (2)
1010 11 1 (1) 3 (7) 2 (3) 2 (1) 3 (3)
1019 1 1 (1)
1021 2 2 (2)
1043 1 1 (0.4)
1044 3 3 (3)
1054 2 2 (1)
1059 1 1 (0.4)
emm77 1028 4 4 (10)
9 2 1 (2) 1 (1)
10 3 3 (1)
emm75 1036 1 1 (1)
1060 1 1 (0.4)
emm33 1046 2 2 (1)
1052 2 2 (1)
emm78 1042 1 1 (0.4)
emm28 1033 1 1 (1)
emm9 1042 2 2 (2)
emm60 8 1 1 (1)
NT 42 1 1 (1)
1018 1 1 (2)
62 3 3 (1)
71 1 1 (0.4)
1005 2 2 (1)
1012 2 2 (1)
1033 2 2 (1)
1042 1 1 (0.4)
1043 3 3 (1)
1044 3 3 (1)
1045 1 1 (0.4)
1049 3 3 (1)
1050 1 1 (0.4)
1051 1 1 (0.4)
1055 1 1 (0.4)
1058 1 1 (0.4)
1061 2 2 (2)
83 1 1 (1)
26 1 1 (1)
iMLS emm1 1031 1 1 (2)
emm22 1 2 2 (3)
emm4 10 1 1 (1)
emm9 61 1 1 (1)
emm77 9 2 1 (1) 1 (0.4)
10 1 1 (0.4)
50 2 1 (1) 1 (0.4)
emm12 57 1 1 (0.4)
emm18 1048 1 1 (0.4)
emm89 77 1 1 (1)
NT new 1 1 1 (2)
63 1 1 (0.4)
49 3 3 (3)

*PFGE profile numbers from 1-100 designate restriction with SmaI and above 1,000 restriction profiles generated with SfiI.
†NT, non-typeable.

Main Article

1A preliminary account of this work was presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30–November 2, 2004, Washington DC, USA.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO